Sclerosing agent

This page covers all Sclerosing agent drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Vein endothelium (non-receptor mediated tissue damage).

Targets

Vein endothelium (non-receptor mediated tissue damage)

Marketed (6)

• Foam sclerotherapy · Imperial College London · Vascular/Dermatology
  Foam sclerotherapy involves injecting a sclerosing agent in foam form into abnormal veins to cause inflammation and fibrosis, leading to vein closure and reabsorption.
• Varithena® · Boston Scientific Corporation · Cardiovascular / Vascular
  Varithena is a microfoam formulation of polidocanol that destroys varicose veins by causing endothelial damage and subsequent vein closure.
• sclerotherapy with aethoxysclerol foam · Medical University of Vienna · Vascular/Dermatology
  Aethoxysclerol foam causes endothelial damage and thrombosis within varicose veins, leading to vessel fibrosis and obliteration.
• talc powder · Chinese University of Hong Kong · Oncology
  Talc powder acts as a sclerosing agent that causes inflammation and adhesion of serosal surfaces to prevent fluid reaccumulation.
• Talc Slurry Pleurodesis · Memorial Healthcare System · Oncology / Pulmonology
  Talc slurry induces chemical pleurodesis by causing inflammation and fibrosis of the pleural surfaces, obliterating the pleural space to prevent fluid reaccumulation.
• Polidocanol with Glucose · UPECLIN HC FM Botucatu Unesp · Vascular/Dermatology
  Polidocanol is a sclerosing agent that causes endothelial damage and fibrosis of blood vessel walls, used in combination with glucose as a sclerosant for varicose veins and other vascular lesions.

Phase 3 pipeline (3)

• polidocanol injectable foam, 1.0% · Boston Scientific Corporation · Cardiovascular
  Polidocanol works by causing endothelial damage and subsequent thrombosis in the treated vein, leading to fibrosis and closure.
• Injection Sclerotherapy · Gulab Devi Hospital · Vascular/Dermatology
  Injection sclerotherapy works by injecting a sclerosing agent directly into abnormal blood vessels or varicose veins to cause inflammation, fibrosis, and obliteration of the vessel.
• polidocanol injectable foam, 0.5% · Boston Scientific Corporation · Dermatology
  Polidocanol works by causing endothelial damage and subsequent thrombosis in the targeted vein.